09:49 AM EST - Trimel Pharmaceuticals Corporation : announced that Health Canada has provided the Company with a No Objection Letter, thereby permitting patient enrolment in Canada for the Tefina™ Phase II Ambulatory study exploring a "use-as-required" treatment for women experiencing Female Orgasmic Disorder, or more commonly referred to as anorgasmia. Trimel Pharmaceuticals Corporation
shares T.TRL are trading unchanged at $3.00.
